{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:17:18Z","timestamp":1791058638351,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["09150161810018"],"award-info":[{"award-number":["09150161810018"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Trace"},{"DOI":"10.13039\/501100006680","name":"Takeda Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006680","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["V0000319"],"award-info":[{"award-number":["V0000319"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009281","name":"Fondation Thierry Latran","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000406","name":"Motor Neurone Disease Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000406","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41431-026-02208-5","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:07:41Z","timestamp":1785258461000},"page":"1590-1594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tofersen treatment in respiratory onset amyotrophic lateral sclerosis and a variant of uncertain significance in SOD1; a case report"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0198-5740","authenticated-orcid":false,"given":"Sean W.","family":"Willemse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9606-0531","authenticated-orcid":false,"given":"Koen C.","family":"Demaegd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Koole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben P. A.","family":"van Eijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5860-1533","authenticated-orcid":false,"given":"Wouter","family":"van Rheenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5572-9657","authenticated-orcid":false,"given":"Jan H.","family":"Veldink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard H.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7709-5883","authenticated-orcid":false,"given":"Michael A.","family":"van Es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"2208_CR1","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","volume":"390","author":"MA van Es","year":"2017","unstructured":"van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084\u201398. https:\/\/doi.org\/10.1016\/S0140-6736(17)31287-4.","journal-title":"Lancet"},{"key":"2208_CR2","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022;387:1099\u2013110. https:\/\/doi.org\/10.1056\/NEJMoa2204705.","journal-title":"N Engl J Med"},{"key":"2208_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"key":"2208_CR4","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1002\/humu.24088","volume":"41","author":"SV Tavtigian","year":"2020","unstructured":"Tavtigian SV, Harrison SM, Boucher KM, Biesecker LG. Fitting a naturally scaled point system to the ACMG\/AMP variant classification guidelines. Hum Mutat. 2020;41:1734\u20137. https:\/\/doi.org\/10.1002\/humu.24088.","journal-title":"Hum Mutat"},{"key":"2208_CR5","doi-asserted-by":"publisher","unstructured":"Willemse SW, Hollak CEM, Reijnhout ND, Reparon-Schuijt CC, Pisters-van Roy AAMG, Demaegd KC, et al. Fast and controlled access to tofersen for SOD1 -related amyotrophic lateral sclerosis in the Netherlands; experiences using the orphan drug access protocol. Amyotrophic Lateral Sclerosis Frontotemporal Degeneration. 2026:1\u20133. https:\/\/doi.org\/10.1080\/21678421.2026.2655738","DOI":"10.1080\/21678421.2026.2655738"},{"key":"2208_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamaneurol.2013.593","volume":"70","author":"L Winer","year":"2013","unstructured":"Winer L, Srinivasan D, Chun S, Lacomis D, Jaffa M, Fagan A, et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013;70:201\u20137. https:\/\/doi.org\/10.1001\/jamaneurol.2013.593.","journal-title":"JAMA Neurol"},{"key":"2208_CR7","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","volume":"54","author":"J Kuhle","year":"2016","unstructured":"Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius \u00c5, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016;54:1655\u201361. https:\/\/doi.org\/10.1515\/cclm-2015-1195.","journal-title":"Clin Chem Lab Med"},{"key":"2208_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1212\/01.wnl.0000194316.91908.8a","volume":"66","author":"F Kimura","year":"2006","unstructured":"Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265\u20137. https:\/\/doi.org\/10.1212\/01.wnl.0000194316.91908.8a.","journal-title":"Neurology"},{"key":"2208_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S1474-4422(18)30089-9","volume":"17","author":"HJ Westeneng","year":"2018","unstructured":"Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423\u201333. https:\/\/doi.org\/10.1016\/S1474-4422(18)30089-9.","journal-title":"Lancet Neurol"},{"key":"2208_CR10","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/jnnp.2011.244939","volume":"82","author":"MHB Huisman","year":"2011","unstructured":"Huisman MHB, de Jong SW, van Doormaal PTC, Weinreich SS, Schelhaas HJ, van der Kooi AJ, et al. Population-based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry. 2011;82:1165\u201370. https:\/\/doi.org\/10.1136\/jnnp.2011.244939.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2208_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-023-06045-0","volume":"625","author":"S Chen","year":"2024","unstructured":"Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature. 2024;625:92\u2013100. https:\/\/doi.org\/10.1038\/s41586-023-06045-0.","journal-title":"Nature"},{"key":"2208_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1080\/21678421.2019.1606244","volume":"20","author":"RAA van der Spek","year":"2019","unstructured":"van der Spek RAA, van Rheenen W, Pulit SL, Kenna KP, van den Berg LH, Veldink JH. The project MinE databrowser: bringing large-scale whole-genome sequencing in ALS to researchers and the public. Amyotroph Lateral Scler Frontotemp Degener. 2019;20:432\u201340. https:\/\/doi.org\/10.1080\/21678421.2019.1606244.","journal-title":"Amyotroph Lateral Scler Frontotemp Degener"},{"key":"2208_CR13","doi-asserted-by":"publisher","unstructured":"Ruffo P, Perrone B, Conforti FL SOD-1 Variants in amyotrophic lateral sclerosis: systematic re-evaluation according to ACMG-AMP guidelines. Genes. MDPI;13. 2022. https:\/\/doi.org\/10.3390\/genes13030537","DOI":"10.3390\/genes13030537"},{"key":"2208_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102495","volume":"69","author":"M Wiesenfarth","year":"2024","unstructured":"Wiesenfarth M, Dorst J, Brenner D, Elmas Z, Parlak \u00d6, Uzelac Z, et al. Effects of tofersen treatment in patients with SOD1-ALS in a \u201creal-world\u201d setting - a 12-month multicenter cohort study from the German early access program. EClinicalMedicine. 2024;69:102495. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102495.","journal-title":"EClinicalMedicine"},{"key":"2208_CR15","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.1007\/s00415-024-12437-7","volume":"271","author":"M Sabatelli","year":"2024","unstructured":"Sabatelli M, Cerri F, Zuccarino R, Patanella AK, Bernardo D, Bisogni G, et al. Long-term treatment of SOD1 ALS with tofersen: a multicentre experience in 17 patients. J Neurol. 2024;271:5177\u201386. https:\/\/doi.org\/10.1007\/s00415-024-12437-7.","journal-title":"J Neurol"},{"key":"2208_CR16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s43856-024-00573-0","volume":"4","author":"JH Weishaupt","year":"2024","unstructured":"Weishaupt JH, K\u00f6rtv\u00e9lyessy P, Schumann P, Valkadinov I, Weyen U, Hesebeck-Brinckmann J, et al. Tofersen decreases neurofilament levels, supporting the pathogenesis of the SOD1 p.D91A variant in amyotrophic lateral sclerosis patients. Commun Med. 2024;4:150. https:\/\/doi.org\/10.1038\/s43856-024-00573-0.","journal-title":"Commun Med"},{"key":"2208_CR17","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1212\/01.wnl.0000188760.53922.05","volume":"65","author":"T Sato","year":"2005","unstructured":"Sato T, Nakanishi T, Yamamoto Y, Andersen PM, Ogawa Y, Fukada K, et al. Rapid disease progression correlates with instability of mutant SOD1 in familial ALS. Neurology. 2005;65:1954\u20137. https:\/\/doi.org\/10.1212\/01.wnl.0000188760.53922.05.","journal-title":"Neurology"},{"key":"2208_CR18","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1212\/01.wnl.0000345363.65799.35","volume":"72","author":"L Zinman","year":"2009","unstructured":"Zinman L, Liu HN, Sato C, Wakutani Y, Marvelle AF, Moreno D, et al. A mechanism for low penetrance in an ALS family with a novel SOD1 deletion. Neurology. 2009;72:1153\u20139. https:\/\/doi.org\/10.1212\/01.wnl.0000345363.65799.35.","journal-title":"Neurology"},{"key":"2208_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/0960-8966(96)00353-7","volume":"6","author":"BA Hosler","year":"1996","unstructured":"Hosler BA, Nicholson GA, Sapp PC, Chin W, Orrell RW, De Belleroche JS, et al. Three novel mutations and two variants in the gene for Cu\/Zn superoxide dismutase in familial amyotrophic lateral sclerosis. Neuromuscul Disord. 1996;6:361\u20136. https:\/\/doi.org\/10.1016\/0960-8966(96)00353-7.","journal-title":"Neuromuscul Disord"},{"key":"2208_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/genes11101123","volume":"11","author":"S Lattante","year":"2020","unstructured":"Lattante S, Marangi G, Doronzio PN, Conte A, Bisogni G, Zollino M, et al. High-throughput genetic testing in ALS: The challenging path of variant classification considering the acmg guidelines. Genes. 2020;11:1\u201331. https:\/\/doi.org\/10.3390\/genes11101123.","journal-title":"Genes"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02208-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02208-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02208-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:57:54Z","timestamp":1791017874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02208-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2208"],"URL":"https:\/\/doi.org\/10.1038\/s41431-026-02208-5","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Data was collected as part of the Dutch Motor Neuron Disease registry, which was approved by the medical ethical committee of the University Medical Centre Utrecht (NedMec) with reference 19-190. Written informed consent for publication of their clinical details was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal.interests.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}